IMPAHCT: A Phase 2b/3, Randomized, Double-Blind, Placebo-Controlled, 24-Week Dose Ranging and Confirmatory Study to Evaluate the Safety and Efficacy of AV-101 in patients with Pulmonary Arterial Hypertension (PAH). (NCT05036135)
IMPAHCT
This trial is No longer recruiting
Registration number NCT05036135
Program & service
This trial is being run with the Heart & Lung service, and as part of the Respiratory program.
Trial phase
Phase 2
Trial participation type
This trial has been designed for the Clinical Research of a Drug.
Principal investigator
Dr Helen Whitford
More information
To find out more about this clinical trial, please review full details on the ANZCTR website.
View on ANZCTR